Sanofi has gained FDA approval of its subcutaneous version of Sarclisa, which can be delivered manually or by way of an on-body injector. The nod gives the multiple myeloma treatment a boost in its competition with Johnson & Johnson’s powerhouse Darzalex.
Source: FiercePharma
